• Sabutoclax: Pan-Bcl-2 Inhibitor for Advanced Apoptosis Assay

  2026-04-25

  Sabutoclax stands out among pan-Bcl-2 inhibitors for its multi-target potency, superior cell permeability, and translational value in both in vitro and in vivo cancer models. This guide delivers actionable workflows and troubleshooting tips for maximizing apoptosis induction and assay fidelity, informed by leading-edge research.

• DIDS: Unlocking Chloride Channel Biology for Translational I

  2026-04-24

  This thought-leadership article positions DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) at the intersection of mechanistic insight and translational strategy. Bridging evidence from recent metastasis research and vascular, neuroprotective, and oncology models, we dissect how precision chloride channel modulation is reshaping experimental designs and therapeutic innovation. The article uniquely integrates rigorous numeric evidence, protocol guidance, and a forward-looking perspective, highlighting the competitive and practical advantages of APExBIO's DIDS for translational researchers.

• GI 254023X: Unleashing Selective ADAM10 Inhibition in Resear

  2026-04-24

  GI 254023X stands out as a highly selective ADAM10 inhibitor, empowering researchers to dissect signaling, barrier integrity, and apoptosis pathways with unparalleled specificity. Its robust workflow compatibility and precision enable reproducible results in vascular, neurodegenerative, and oncology models, setting new standards for translational research.

• Reliable Live-Cell Golgi Imaging with Golgi-Tracker Green

  2026-04-23

  This article provides a scenario-driven, evidence-based guide for biomedical researchers using Golgi-Tracker Green (SKU B8813) in live-cell Golgi apparatus labeling, sphingolipid metabolism analysis, and lipid transport pathway visualization. It details best practices in workflow optimization, probe selection, and data interpretation, highlighting how APExBIO’s formulation offers superior photostability and specificity for reproducible results.

• Nonivamide: TRPV1 Agonism for Oncology and Neuroimmune Resea

  2026-04-23

  This article delivers strategic guidance and mechanistic insights for translational researchers exploring Nonivamide, a capsaicin analog and selective TRPV1 agonist, as a dual-action tool for cancer and neuroimmune research. Integrating recent evidence on TRPV1 signaling, tumor growth inhibition, and sensory neuron modulation, the piece highlights validated protocols, competitive context, and future directions, uniquely bridging oncology and inflammation research.

• SGI-1027 Induces Apoptosis via DNMT1 Inhibition in Huh7 Cell

  2026-04-22

  This study demonstrates that SGI-1027, a non-nucleoside DNMT inhibitor, induces apoptosis in Huh7 hepatocellular carcinoma cells chiefly through mitochondrial pathways, with minimal cell cycle disruption. The findings highlight the therapeutic potential of DNMT1 inhibition in cancer models and provide a mechanistic framework for future epigenetic therapies.

• ER Stress-Driven Induction of Prometastatic States in Tumors

  2026-04-22

  This study uncovers how tumor cells surviving imminent cell death can transition into stable, prometastatic states through ER stress, reprogramming, and cytokine signaling. The findings illuminate new mechanisms underlying metastatic initiation and highlight potential intervention targets within the tumoral ecosystem.

• IMPDH-Dependent Nucleotide Biosynthesis Fuels PEDV Replicati

  2026-04-21

  This study demonstrates that porcine epidemic diarrhea virus (PEDV) exploits host IMPDH-dependent guanine nucleotide biosynthesis to support its replication. Both genetic and pharmacological inhibition of IMPDH, particularly with Merimepodib (VX-497), sharply reduces viral propagation, establishing IMPDH as a promising host-directed antiviral target.

• FLAG tag Peptide (DYKDDDDK): Precision Tag for Protein Purif

  2026-04-21

  The FLAG tag Peptide (DYKDDDDK) enables highly specific, gentle purification and detection of recombinant proteins. Its unique sequence and enterokinase-cleavage site optimize elution and workflow flexibility. This article details quantitative benchmarks, best-use protocols, and evidence-based limitations, supporting reliable application in molecular biology.

• THZ1: Covalent CDK7 Inhibitor Workflows for Cancer Biology

  2026-04-20

  THZ1, a potent covalent CDK7 inhibitor from APExBIO, unlocks precision transcriptional control and robust antiproliferative effects in cancer models, particularly T-cell acute lymphoblastic leukemia (T-ALL). This article translates recent mechanistic and workflow insights into actionable experimental protocols, troubleshooting guidance, and practical assay enhancements.

• Probenecid for Multidrug Resistance and Neuroprotection Rese

  2026-04-20

  Probenecid (4-(dipropylsulfamoyl)benzoic acid) stands out as a dual-action biochemical tool for overcoming multidrug resistance in tumor models and mitigating neuronal damage in ischemia/reperfusion injury. This guide translates cutting-edge mechanistic evidence and bench-proven workflows into actionable protocols, helping researchers maximize assay integrity and reproducibility.

• Carfilzomib (PR-171) for Proteasome Inhibition in Cancer Ass

  2026-04-19

  Carfilzomib (PR-171) offers bench scientists an irreversible, nanomolar-potency tool for dissecting proteasome-mediated cell death pathways. This guide translates cutting-edge preclinical findings and troubleshooting insights into actionable workflows, helping you optimize apoptosis induction and proteasome inhibition in diverse cancer research contexts.

• AICAR and AMPK: Precision Tools for Macrophage Polarization

  2026-04-18

  Explore how AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) uniquely enables targeted AMPK activation to dissect macrophage polarization and inflammation in metabolic disease models. This in-depth review draws on the latest mechanistic evidence and practical assay insights.

• SC 79: Advanced Akt Activation for Neuroprotection & Metabol

  2026-04-17

  Explore how SC 79, a potent Akt activator, enables groundbreaking research in neuroprotection and metabolic disease. This article offers a unique, assay-driven perspective on SC 79’s mechanistic advantages and translational potential.

• CDC42 Regulates HBV Entry via NTCP Trafficking and Macropino

  2026-04-16

  Cui et al. reveal that CDC42, a Rho GTPase, facilitates hepatitis B virus (HBV) entry into hepatocytes through Rab11-dependent NTCP trafficking and by promoting macropinocytosis, independent of the canonical clathrin-mediated pathway. These insights highlight new mechanistic targets for antiviral strategies and deepen our understanding of HBV–host interactions.

14622 records 1/975 page Next 12345 下5页 Last page